WANY
CYTK icon

Wealthspire Advisors (New York)’s Cytokinetics CYTK Stock Holding History

Wealthspire Advisors (New York)’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-375
Closed -$20.6K – 1468
2025
Q3 		$20.6K Buy
+375
New +$15.4K ﹤0.01% 1674

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wealthspire Advisors (New York)'s CYTK Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of Cytokinetics (CYTK) in Q4 2025, closing a stake of 375 shares — an estimated $20.6K sold.

Wealthspire Advisors (New York) first reported a position in CYTK in Q3 2025 and held it in 1 quarter. The position peaked at $20.6K in Q3 2025. 430 funds tracked by Wall St. Rank hold CYTK as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining Cytokinetics position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 375 Cytokinetics shares in Q4 2025, an estimated $20.6K.
  • Wealthspire Advisors (New York) first reported a position in Cytokinetics in Q3 2025 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s Cytokinetics position peaked at $20.6K in Q3 2025.
  • 430 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.